Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.030 AlteredExpression disease BEFREE Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma. 28433697 2017
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.030 AlteredExpression disease BEFREE Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma. 28433697 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 AlteredExpression group BEFREE RAB22A, a member of RAS oncogene family, has been found to be significantly upregulated in multiple human cancers. 27690221 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.030 Biomarker disease BEFREE The DNMT1/miR-211/RAB22A axis provides a novel insight into the pathogenesis of melanoma, particularly in the EMT process. 27237979 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.030 Biomarker disease BEFREE In addition, RAB22A was found to be a target of miR-203, a tumor suppressive miRNA in melanoma. 27690221 2016
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.030 AlteredExpression disease BEFREE Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis. 26382657 2015
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.030 AlteredExpression disease BEFREE Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis. 26382657 2015
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.030 AlteredExpression disease BEFREE Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis. 26382657 2015
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.030 Biomarker disease BEFREE In breast cancer patients, RAB22A mRNA overexpression in the primary tumor is associated with decreased overall and metastasis-free survival and, in an orthotopic mouse model, RAB22A knockdown impairs breast cancer metastasis. 24938788 2014
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.030 Biomarker disease BEFREE Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A. 25550792 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.030 Biomarker disease BEFREE In breast cancer patients, RAB22A mRNA overexpression in the primary tumor is associated with decreased overall and metastasis-free survival and, in an orthotopic mouse model, RAB22A knockdown impairs breast cancer metastasis. 24938788 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.030 Biomarker disease BEFREE Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A. 25550792 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.030 Biomarker disease BEFREE Primary melanoma in patients greater than 60 years old was characterized by the increased expression of miRs regulating TLR-MyD88-NF-kappaB pathway (hsa-miR-199a), RAS/RAB22A pathway (hsa-miR-204); growth differentiation and migration (hsa-miR337), epithelial mesenchymal transition (EMT) (let-7b, hsa-miR-10b/10b*), invasion and metastasis (hsa-miR-10b/10b*), hsa-miR-30a/e*, hsa-miR-29c*; cellular matrix components (hsa-miR-29c*); invasion-cytokinesis (hsa-miR-99b*) compared to melanoma of younger patients. 20302635 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.020 Biomarker disease BEFREE The preliminary findings revealed that miR-193b may have an important role in the process in colon cancer cell cycle and migration by the RAB22A-Ras signaling pathway, thus providing a theoretical basis for miR-193b as a potential molecular target for colon cancer treatment. 31007734 2019
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.020 Biomarker disease BEFREE The preliminary findings revealed that miR-193b may have an important role in the process in colon cancer cell cycle and migration by the RAB22A-Ras signaling pathway, thus providing a theoretical basis for miR-193b as a potential molecular target for colon cancer treatment. 31007734 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 AlteredExpression group BEFREE In addition, the present findings suggested that the increased expression of miR-193b by RAB22A, inhibited downstream proteins involved in the Ras signaling pathway, including the Ras and extracellular signal-related kinase which may inhibit cancer proliferation and migration. 31007734 2019
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.020 Biomarker disease BEFREE Furthermore, Rab22A reversal downregulated the inhibitory effect of miR-520b. miR-520b expression was downregulated in NSCLC, which was negatively correlated with lymph node metastasis and TNM staging. miR-520b targeted on Rab22A to work as a tumor suppressor, inhibiting tumor proliferation and metastasis. 30402147 2018
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.020 AlteredExpression disease BEFREE In this study, we demonstrate that the upregulation of RAB22A is associated with breast cancer progression and lymph node metastasis. 30272274 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE On the whole, the findings of this study demonstrate the critical role that miR-193b plays in the regulation of RAB22A-mediated exosome function during cancer growth and metastasis, which may have significant implications on cancer therapy. 30272274 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.020 Biomarker disease BEFREE The present work provides the first evidence of a UCA1-miR-204-5p-CREB1/BCL2/RAB22A regulatory network in CRC and reveals that UCA1 and CREB1 are potential new oncogenes and prognostic factors for CRC. 27046651 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.020 AlteredExpression disease BEFREE LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. 27484896 2016
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.020 AlteredExpression disease BEFREE LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. 27484896 2016
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.020 AlteredExpression disease BEFREE LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. 27484896 2016
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.020 Biomarker disease BEFREE Our results demonstrate for the first time that miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer. 25294901 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.020 Biomarker disease BEFREE MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. 25460499 2014